Loading the session
Loading the session
Loading instrument
$200.91
−1.40%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 04:04 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +25.6% (SPY −1.6%). 3 months: +24.2% (SPY −0.4%). 1 year: +24.6% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ICLR, SPY · as of 4 Nov 2026
Closed at $203.11 on 4 Nov 2026: 7.3% below the 52-week high of $219.04 (29 Oct 2026) and 205.1% above the low of $66.57 (12 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
The 4 Nov 2026 close of $203.11 was 16.8% above its 50-day average ($173.91) and 39.0% above its 200-day average ($146.16). It has closed above the 200-day for 94 sessions, since 24 Jun 2026. The 50-day average crossed above the 200-day on 24 Jul 2026, 72 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
3.0M shares were sold short at the 15 Oct 2026 settlement, 3.9% of the 76.4M shares outstanding; covering them would take 3.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
October 28, 2026
+17.04%February 12, 2026
−39.85%October 24, 2024
−21.03%